{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:23:10Z","timestamp":1791400990572,"version":"4.3.3"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KEREM19KO"],"award-info":[{"award-number":["KEREM19KO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WILSCH20K0"],"award-info":[{"award-number":["WILSCH20K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor (VX-445)\u2013tezacaftor (VX-661)\u2013ivacaftor (VX-770) (ETI) enables the effective rescue of CFTR function in people with the F508del mutation and 177 other US Food and Drug Administration-approved alleles. However, the effect of modulator combination treatment on many rare CFTR mutations is mostly unknown. Furthermore, rare CFTR mutations may not require all ETI components to reach maximal correction. This can be studied in intestinal organoids derived from patients carrying rare mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Intestinal organoids were generated from six patients carrying the Q1100P and\/or K163E alleles, not receiving ETI. Measurements of the response to ETI or combination of its components were performed in three-dimensional organoids by forskolin-induced swelling and in two-dimensional monolayers by short-circuit current. Based on these results, patients initiated off-label ETI treatment. Clinical data before and after treatment were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Functional measurements showed that both mutations are responsive to ETI. The results further showed that VX-445 had a dramatic effect on K163E function. Both Q1100P and K163E mutations achieved clinically significant CFTR activity levels with VX-661+VX-445, without benefit from VX-770. Following these results patients initiated off-label ETI treatment, resulting in significant and sustained clinical improvements, in all patients, in lung function (forced expiratory volume in 1\u2005s and lung clearance index), body mass index and sweat chloride.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results support that CFTR function measurements in patient-derived intestinal organoids carrying rare CFTR alleles can detect potential responders to modulator treatment and serve as the basis for drug approval by health providers. Furthermore, this approach allows for patient-specific optimisation of modulator combinations, minimising unnecessary exposure to ineffective treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01308-2024","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:20:27Z","timestamp":1741872027000},"page":"01308-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The response of rare CFTR mutations to specific modulator combinations"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-2246","authenticated-orcid":false,"given":"Noemie","family":"Stanleigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-3398","authenticated-orcid":false,"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryeh","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Sebbag-Sznajder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-3686","authenticated-orcid":false,"given":"Liron","family":"Birimberg-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Pevzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Bar-Yoseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-386X","authenticated-orcid":false,"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wilschanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batsheva","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025102704052331000_11.5.01308-2024.1","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025102704052331000_11.5.01308-2024.2","unstructured":"Cystic Fibrosis Mutation Database (CFTR1) . CFMDB statistics. Date last accessed: October 2024. Date last updated: 25 April 2011. www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"2025102704052331000_11.5.01308-2024.3","unstructured":"CFTR2 clinical and functional translation of CFR. Date last accessed: October 2024. Date last updated: 25 September 2024. cftr2.org"},{"key":"2025102704052331000_11.5.01308-2024.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.004"},{"key":"2025102704052331000_11.5.01308-2024.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216"},{"key":"2025102704052331000_11.5.01308-2024.6","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor\u2013tezacaftor\u2013ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"2025102704052331000_11.5.01308-2024.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.009"},{"key":"2025102704052331000_11.5.01308-2024.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.12.005"},{"key":"2025102704052331000_11.5.01308-2024.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025102704052331000_11.5.01308-2024.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025102704052331000_11.5.01308-2024.11","unstructured":"BusinessWire . Vertex announces FDA approvals of TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor\/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for use in people with CF with certain rare mutations. Date last accessed: October 2024. Date last updated: 21 December 2020. www.businesswire.com\/news\/home\/20201221005675\/en\/"},{"key":"2025102704052331000_11.5.01308-2024.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.07.050"},{"key":"2025102704052331000_11.5.01308-2024.13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/jpm11070643","article-title":"A precision medicine approach to optimize modulator therapy for rare CFTR folding mutants","volume":"11","author":"Veit","year":"2021","journal-title":"J Pers Med"},{"key":"2025102704052331000_11.5.01308-2024.14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210358"},{"key":"2025102704052331000_11.5.01308-2024.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3201"},{"key":"2025102704052331000_11.5.01308-2024.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.068"},{"key":"2025102704052331000_11.5.01308-2024.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02529-2017"},{"key":"2025102704052331000_11.5.01308-2024.18","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2019"},{"key":"2025102704052331000_11.5.01308-2024.19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2018.02.007","article-title":"Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity","volume":"17","author":"Zomer-van Ommen","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2025102704052331000_11.5.01308-2024.20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0873-2159(15)30514-6","article-title":"Cystic fibrosis\u2013clinical features of a sample of Portuguese patients","volume":"11","author":"Guardiano","year":"2005","journal-title":"Rev Port Pneumol"},{"key":"2025102704052331000_11.5.01308-2024.21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s11033-018-4361-y","article-title":"Description of rare mutations and a novel variant in Brazilian patients with cystic fibrosis: a case series from a referral center in the Bahia State","volume":"45","author":"Mota","year":"2018","journal-title":"Mol Biol Rep"},{"key":"2025102704052331000_11.5.01308-2024.22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms23010024","article-title":"Rare trafficking CFTR mutations involve distinct cellular retention machineries and require different rescuing strategies","volume":"23","author":"Ramalho","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025102704052331000_11.5.01308-2024.23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12887-019-1903-y","article-title":"A comprehensive overview of the cystic fibrosis on the island of S\u00e3o Miguel (Azores, Portugal)","volume":"20","author":"Rosa","year":"2020","journal-title":"BMC Pediatr"},{"key":"2025102704052331000_11.5.01308-2024.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.2006.00310.x"},{"key":"2025102704052331000_11.5.01308-2024.25","doi-asserted-by":"crossref","first-page":"9812074","DOI":"10.1155\/2021\/9812074","article-title":"Next-generation sequencing for molecular diagnosis of cystic fibrosis in a Brazilian cohort.","volume":"2021","author":"Cambraia","year":"2021","journal-title":"Dis Markers"},{"key":"2025102704052331000_11.5.01308-2024.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000237793.19868.97"},{"key":"2025102704052331000_11.5.01308-2024.27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/ijns4030022","article-title":"Cystic fibrosis newborn screening in Portugal: PAP value in populations with stringent rules for genetic studies","volume":"4","author":"Marc\u00e3o","year":"2018","journal-title":"Int J Neonatal Screen"},{"key":"2025102704052331000_11.5.01308-2024.28","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1038\/s41598-019-42404-6","article-title":"Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools","volume":"9","author":"Pereira","year":"2019","journal-title":"Sci Rep"},{"key":"2025102704052331000_11.5.01308-2024.29","doi-asserted-by":"crossref","first-page":"e0133890","DOI":"10.1371\/journal.pone.0133890","article-title":"Distribution of cystic fibrosis transmembrane conductance regulator (CFTR) mutations in a cohort of patients residing in Palestine.","volume":"10","author":"Siryani","year":"2015","journal-title":"PLoS One"},{"key":"2025102704052331000_11.5.01308-2024.30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704052331000_11.5.01308-2024.31","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00716-2021"},{"key":"2025102704052331000_11.5.01308-2024.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02774-2020"},{"key":"2025102704052331000_11.5.01308-2024.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202101-0090LE"},{"key":"2025102704052331000_11.5.01308-2024.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.011"},{"key":"2025102704052331000_11.5.01308-2024.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.166955"},{"key":"2025102704052331000_11.5.01308-2024.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.014"},{"key":"2025102704052331000_11.5.01308-2024.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03994-5"},{"key":"2025102704052331000_11.5.01308-2024.38","doi-asserted-by":"publisher","DOI":"10.1124\/mol.118.111799"},{"key":"2025102704052331000_11.5.01308-2024.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.02.006"},{"key":"2025102704052331000_11.5.01308-2024.40","doi-asserted-by":"publisher","DOI":"10.1111\/JCPT.13329"},{"key":"2025102704052331000_11.5.01308-2024.41","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26527"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01308-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:07:34Z","timestamp":1761563254000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01308-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1183\/23120541.01308-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01308-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}